Earnings
Arrowhead's CEO Blames Rival's Execution As His Own Launch Faces A Reimbursement Bottleneck
Management defined launch speed through prescriptions, prescribers and coverage, while saying sales guidance was premature.
Arrowhead Pharmaceuticals (ARWR) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Earnings
Management defined launch speed through prescriptions, prescribers and coverage, while saying sales guidance was premature.
SEC Filings
Annual costs included a $215 million review voucher that Arrowhead retains while pursuing a broader use for REDEMPLO.
SEC Filings
The RNAi drugmaker's new $400 million term loan matures in November 2031 and carries no required sweeps of partnership or product revenue.